TARGET AUDIENCE: Medical oncologists

GLOBAL LEARNING OBJECTIVES:
Upon completion of this activity, participants should be able to:

• Describe recent clinical trial data linking diet and risk for recurrence.
• Evaluate the emerging data on various adjuvant chemotherapy approaches, including
  dose-dense treatment and other taxane-based regimens and explain the absolute risks and
  benefits of adjuvant chemotherapy regimens to patients.
• Counsel postmenopausal patients with ER-positive breast cancer about the risks and benefits
  of adjuvant aromatase inhibitors and of sequencing aromatase inhibitors after tamoxifen, and
  counsel premenopausal women about the risks and benefits of adjuvant ovarian suppression
  alone or with other endocrine interventions.

CME EVALUATION: An evaluation form will be given to each participant at the conclusion of this activity.

ACCREDITATION STATEMENT: Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT: Research To Practice designates this educational activity for a maximum of 2.5 category 1 credits toward the AMA Physician’s Recognition Award. Each physician should claim only those credits that he/she actually spent in the activity.

DISCLOSURE POLICY: As a provider accredited by the Accreditation Council for Continuing Medical Education, it is the policy of Research To Practice to require the disclosure of any significant financial interest or any other relationship the sponsor or faculty members have with the manufacturer(s) of any commercial product(s) discussed in an educational presentation. Financial disclosures and disclosures of discussions of unlabeled/unapproved uses of drugs or devices will be provided in meeting course materials.

EDUCATIONAL SUPPORT: This event is supported by education grants from Amgen Inc and AstraZeneca Pharmaceuticals LP.